| Chronic verapamil therapy in pediatrie and young adult patients with hypertrophic cardiomyopathy | |
Abstract/OtherAbstract
:
|
Oral verapamil, 5.2 +/- 1.1 mg/kg/day (range 2.8 to 7), was administered to 13 pediatric patients with hypertrophic Cardiomyopathy for 13 +/- 6 months (range 2 to 20). The patients had significant symptomatic improvement on verapamil therapy. Murmur intensity diminished in 6 patients during therapy and left ventricular (LV) electromotive forces on the electrocardiogram diminished in 4, increased in 5 and did not change in 4. Exercise endurance increased from 8.4 +/- 3.9 to 10.9 +/- 2.8 minutes (p < 0.01). Seven patients had ST-segment depression (0.38 +/- 0.28 mV) before verapamil therapy, which improved after verapamil therapy in 5 (0.24 +/- 0.17 mV, p < 0.02). Of 4 patients with exercise-induced ventricular ectopic activity, 3 had diminution or abolishment of ectopy following verapamil. By echocardiography, the patients had an increase in LV end-diastolic dimension from 3.4 +/- 0.7 to 3.9 +/- 0.8 cm (p < 0.01), with no significant change in shortening fraction (46.1 +/- 8.0% vs 44.6 +/- 8.0%). When adjusted for body size and age there was a significant decrease in LV septal thickness (from 106 +/- 70 to 45 +/- 52% of predicted normal values, p < 0.05) and LV posterior wall thickness (from 40 +/- 45 to 5 +/- 26% of predicted normal values p = 0.05) after verapamil. Isovolumic relaxation time decreased from 69 +/- 26 to 42 +/- 19 ms after verapamil (p < 0.01). Systolic anterior motion of the anterior mitral leaflet disappeared in 5 of 8 patients and midsystolic closure of the aortic valve was no longer present in 4 of 8. Chronic oral verapamil appears to be an effective form of therapy for pediatric patients with hypertrophic Cardiomyopathy., Peer Reviewed, http://deepblue.lib.umich.edu/bitstream/2027.42/24807/1/0000233.pdf |
Authors
:
|
Spicer, Robert L., Rocchini, Albert P., Crowley, Dennis C., Rosenthal, Amnon |
Contributors
:
|
Department of Pediatrics and the Clinical Research Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA; Division of Pediatric Cardiology, C. S. Mott Children's Hospital, Ann Arbor, Michigan, USA., Division of Pediatric Cardiology, C. S. Mott Children's Hospital, Ann Arbor, Michigan, USA; Department of Pediatrics and the Clinical Research Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA., Department of Pediatrics and the Clinical Research Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA; Division of Pediatric Cardiology, C. S. Mott Children's Hospital, Ann Arbor, Michigan, USA., Department of Pediatrics and the Clinical Research Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA; Division of Pediatric Cardiology, C. S. Mott Children's Hospital, Ann Arbor, Michigan, USA. |
Publication Detail
:
|
Publisher : Elsevier Type : - Format : 847638 bytes, 3118 bytes, application/pdf, text/plain |
Date Detail
:
|
2006-04-07, 2006-04-07, 1984/06/01 |
Subject
:
|
Internal Medicine and Specialties, Health Sciences |
Coverage
:
|
- |
Relation
:
|
- |
Source
:
|
- |
Copyright Information
:
|
IndexNoFollow |
Other Details
:
|
Languages : en_US |
Export Citation
:
|
APA/MLA Format Download EndNote Download BibTex |
Previous Document: Role of microtobules in the dtilizaiton of low density lipoprotein by cultured rat luteal cells
Next Document: Degradation of the N-term inus and central core of somatostatin (SRIF) by intact rat liver